BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 35

VCCT Inc., Leading the Field of Retinal Regeneration through iPS Cells, Raises 600M Japanese yen ($4M USD) through Third-Party Allotment

By Leave a Comment

Cumulative Funds Raised Amount to Approximately 1.7 billion yen (Approximately $11.3 million USD)

KOBE, Japan — VCCT Inc. (President: Masayo Takahashi) is pleased to announce the completion of a private equity allotment of approximately 600 million yen ($4 million USD). The allotment involved new shares to Sysmex Corporation (President: Kaoru Asano), DAI-DAN CO., LTD. (Representative Director, President: Ichiro Fujisawa), and YASKAWA Electric Corporation (Representative Director, President: Masahiro Ogawa). VCCT will continue to accelerate the development of retinal regenerative medicine together with these partners. [Read more…]

Ajinomoto Co. to Acquire Gene Therapy CDMO Forge Biologics for an Astounding $620 Million

By Leave a Comment

  • Acquisition extends global capabilities in AAV and plasmid gene therapy manufacturing for Ajinomoto, Co. Inc., diversifying and strengthening their current contract development and manufacturing services  
  • Positions Forge Biologics for accelerated long-term growth supporting gene and cell therapy clients worldwide 

[Read more…]

Atsena Therapeutics Receives FDA RMAT Designation for ATSN-101 Gene Therapy

By Leave a Comment

RMAT designation recognizes the potential of ATSN-101 to address unmet medical needs for patients with LCA1
ATSN-101 has demonstrated clinically meaningful improvements in vision at the highest dose with no drug-related serious adverse events 6 months post-treatment in ongoing Phase I/II clinical trial

[Read more…]

NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

By Leave a Comment

TORONTO and HAIFA, Israel  — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a pioneering biotechnology company, is thrilled to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation (ODD) for its ExoPTEN therapy, recognizing the potential of this groundbreaking regenerative therapy for acute spinal cord injury, a condition where effective treatments are limited. [Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0